Q3 Loss Nearly Doubles to $21.9M as R&D Spend Jumps; Cash Lasts Into Q2 2028
CADL sits 93% above its 52-week low of $4.35.
Summary
Candel's Q3 net loss widened to $21.9M from $11.3M a year earlier, driven by R&D expense of $15.6M versus $8.5M and G&A of $7.4M versus $4.7M. The company ended September with $203.1M in cash, up from $119.7M at December 31, 2025, and now says that funds operations into Q2 2028 — extending the runway past the Q1 2028 guide given with Q2 results in August. No new trial data came with the release; the value case still rests on the planned mid-2027 BLA submission for aglatimagene, which the same-day 8-K flagged. The quarter shows spending ramping toward commercial readiness while the balance sheet covers it, so dilution risk near term is low but the loss rate is climbing.
At the time of this announcement, CADL was trading at $8.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $642M. The 52-week trading range was $4.35 to $14.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.